成人超重或肥胖患者每日一次口服25毫克司美格鲁肽的胃肠道耐受性及其与体重减轻的关系：OASIS 4试验的事后分析.pdf

1、Rubino D et al.Presented at the 33rdEuropean Congress on Obesity(ECO 2026),1215 May 2026,Istanbul,Trkiye.Gastrointestinal tolerability of once-daily oral semaglutide 25 mg in adults with overweight or obesity,and the relationship with weight loss:a post hoc analysis of the OASIS 4 trialDomenica Rubi

2、no1,Oscar Birkhan2,Agnieszka Klimek-Abercrombie2,Chaithra Shaji3,Minh Chau Tran2,Sean Wharton41Washington Center for Weight Management and Research,Arlington,VA,USA;2Novo Nordisk A/S,Sborg,Denmark;3Novo Nordisk Global Business Services,Bengaluru,India;4University of Toronto,Toronto,Ontario,CanadaRub

3、ino D et al.Presented at the 33rdEuropean Congress on Obesity(ECO 2026),1215 May 2026,Istanbul,Trkiye.I N C L U D EDI N PO ST ERIntroduction2AE,adverse event;GI,gastrointestinal;GLP-1RA,glucagon-like peptide-1 receptor agonist;s.c.,subcutaneous.1.Wharton S et al.N Engl J Med 2025;393:10771087;2.Bett

4、ge K et al.Diabetes Obes Metab 2017;19:336347;3.Wharton S et al.Diabetes Obes Metab 2022;24:94105.This post hoc analysis of OASIS 4 investigated the relationship between GI AEs and weight loss for oral semaglutide 25 mgPhysicians and patients may query whether GI AEs are,at least in part,responsible

5、 for the weight loss attained with these medicationsIn OASIS 4,once-daily oral semaglutide 25 mg,a GLP-1RA,led to significantly greater body weight loss of 13.6%vs 2.2%with placebo(p0.001,treatment policy estimand;trial product estimand:16.6%vs 2.7%)after 64 weeks in people with overweight or obesit

6、y1GI AEs,most commonly mildtomoderate nausea,are a dose-dependent class effect of GLP-1RAs2Weight loss induced by s.c.semaglutide 2.4 mg has been shown to be independent of GI AEs3However,this has not previously been investigated with oral semaglutideRubino D et al.Presented at the 33rd European Con